Description
Growth Arrested PD-1 / NFAT Reporter - Jurkat Recombinant Cell Line | 79687 | Gentaur US, UK & Europe Disrtribition
Category: Immunotherapy/Cell Line
Application: • Screen for activators or inhibitors of PD-1 signaling in a cellular context. • Characterize the biological activity of PD-1 and its interactions with ligands.
Background: The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and PD-1:PD-L1/2 interaction inhibits T cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes. The cell cycle control system acts like a timer, or a clock, that sets a fixed amount of time for the cell to spend in each phase of the cell cycle. The four major phases of the mammalian cell cycle are G1, S, G2 and M phases. Cell-cycle arrest means the cell enters quiescent stage, where the cell becomes a permanent cell and is no longer active in the process of cell division.
Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human PD-1 (Programmed Cell Death 1, PDCD1, SLEB2, CD279, GenBank Accession #NM_005018). Note: These cells are unable to complete mitosis and are suitable for single use assays. For cells capable of reproducing, please use our PD-1 / NFAT Reporter - Jurkat Recombinant Cell Line, #60535.
Product Type: Cell Line
Shippement Condition: -80°C
